THE SAGE GROUP Announces that Mary L. Yost, President, Will Present Several Lectures on Peripheral Artery Disease (PAD), Critical Limb Ischemia (CLI) and Amputation at the 17th Annual NEW CARDIOVASCULAR HORIZONS (NCVH) Meeting
BEAUFORT SC, May 23, 2016 (BUSINESS WIRE)—Ms. Yost’s lecture titled, “New Research on Peripheral Arterial Disease Risk Factors” will be delivered on June 1, 2016 at 10:00 AM during the NCVH Podiatry and Wound Care Session I: Vascular Disease, Diagnosis and Treatment. Two additional lectures titled “Socio-Economic Costs and Consequences of Amputation“ and “Economic Cost of Peripheral Artery Disease (PAD), Critical Limb Ischemia (CLI) and Venous Disease: How Big is the Market? “ will be presented at Podiatry and Wound Care Session IV: The Business of Wound Care held on June 3rd from 9:45 AM to 11:55 AM.
Ms. Yost delivers a lecture on global CLI epidemiology “The Scope of Critical Limb Ischemia (CLI): A Worldwide Problem” at 10:00 AM during the 12th Annual CLI Summit Session I on June 2. All NCVH sessions will be held at The Roosevelt Waldorf-Astoria in New Orleans, Louisiana.
“I am honored to have the opportunity to speak at this prestigious, multidisciplinary meeting with its special focus on PAD and CLI,” commented Yost. “PAD has been characterized as a ‘global pandemic’. Its rapid spread reflects a combination of factors, particularly the worldwide epidemic of diabetes and the aging population. Unfortunately, CLI, the most severe and deadly form of PAD, and resulting amputations also represent significant global problems. Yet PAD/CLI remain underestimated, underdiagnosed, undertreated and under-researched.”
For more information on NCVH, including the conference program, or to register, visit
NCVH is an educational nonprofit foundation focused on multidisciplinary accredited conferences to advance the field of cardiovascular care using endovascular technologies, pharmacotherapy treatments, peripheral interventions and amputation prevention techniques. With a goal to empower healthcare providers with knowledge of head-to-toe vascular treatments, NCVH strives to promote interdisciplinary teamwork and collaboration to address the continuum of patient care. Additional information: http://www.ncvh.org/index.php
THE SAGE GROUP, a research and consulting company, specializes in atherosclerotic and venous disease in the lower limbs, specifically PAD, CLI, intermittent claudication (IC) and ischemic diabetic foot ulcers (DFU). The most recent research focuses on quantifying the economic and social costs of PAD, CLI and amputation. Additional information: www.thesagegroup.us.
SOURCE: THE SAGE GROUP
Mary Yost 404-520-6652